Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Author:
Publisher
Oxford University Press (OUP)
Subject
Gastroenterology,General Medicine
Link
http://academic.oup.com/ecco-jcc/article-pdf/12/2/245/23611084/jjx143.pdf
Reference68 articles.
1. Assessing response and loss of response to biological therapies in IBD;Am J Gastroenterol,2011
2. Loss of response to anti-tumor necrosis factors: what is the next step;Dig Dis,2014
3. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management;Clin Transl Gastroenterol,2016
4. Vedolizumab as induction and maintenance therapy for ulcerative colitis;GEMINI 1 Study Group;N Engl J Med,2013
5. Vedolizumab for ulcerative colitis and Crohn’s disease: - results and implications of GEMINI studies;Immunotherapy,2014
Cited by 115 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital;Gastroenterología y Hepatología;2024-01
2. Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review;Cureus;2023-11-06
3. Surgical outcomes and stoma-related complications in inflammatory bowel disease in Saudi Arabia: a retrospective study;Annals of Saudi Medicine;2023-11
4. Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study;Crohn's & Colitis 360;2023-09-22
5. Emerging oral drug options for ulcerative colitis;Expert Opinion on Emerging Drugs;2023-07-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3